+44 (0) 753 598 8369 [email protected]

Upcoming Webinar: Health Technology Assessment – Historical Ride and Present Story. Click to Register

Professor Egon Jonsson talks about Health Technology assessment and its historical and present relevance. Click to register

Advancing healthcare by connecting data and research to evidence-based decision making

Our multi-disciplinary experts strive to achieve a fine balance of academic quality and industry professionalism.
We provide efficient and innovative HEOR and RWE services tailored to your needs.

We understand your Needs

This is why we focus on maintaining a perfect balance across the three dimensions of academic and professional efficiency.

Timeliness, Quality assurance and Value for money.

Our Services

ConnectHEOR provides high-quality Health Economics and Outcomes Research (HEOR) and Real World Evidence (RWE) services to generate research-based evidence. We support by demystifying HEOR challenges and efficiently demonstrating a product’s value for internal and external decision making. Check out our services below to know more about our offerings.

1

Decision Modelling

Cutting-edge methods to ensure scientifically robust and user-friendly models

1

RWE & Data Analytics

Analysis of Real World Data to study disease epidemiology and its impact in each phase of product lifecycle

1

Review & Evidence Synthesis

Assessment of different studies within the scope of existing knowledge for a specific objective

1

Market access and Value communication

Effectively communicating the clinical and economic value of healthcare technologies to payers and reimbursement agencies

Latest Publications

Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia

Saiyed M, Byrnes J, Srivastava T, Scuffham P, Downes M

Nov 2020

In the REFLECT trial, lenvatinib showed superior clinical benefits to sorafenib in terms of progression-free survival and was non-inferior for overall survival in the treatment of advanced hepatocellular carcinoma (HCC). The study assessed the cost-effectiveness of lenvatinib compared with sorafenib for patients with advanced HCC in Australia.

Discrete Time Markov Models

Improving Cycle Corrections in Discrete Time Markov Models: A Gaussian Quadrature Approach [Pre Print]

Srivastava T, Strong M, Stevenson MD, Dodd P

Nov 2019

In this study, a novel cycle correction method based on Gaussian Quadrature (GQ) is introduced for Markov Models. A simulation study was conducted to compare the GQ method with existing methods. Fifth order GQ method outperformed other existing methods in 99.8% scenarios.

Volume–Outcome Relationships in Open and Endovascular Repair of Abdominal Aortic Aneurysm: Administrative Data 2006–2018

Tong T, Aber A, Chilcott J, Thokala P et al

Aug 2020

The aim of this study was to analyse real-world hospital-based patient level data (70k+ patients) to investigate and update volume–outcome relationships after open surgical repair (OSR) and endovascular repair (EVAR) of abdominal aortic aneurysm in England.

 

Partner with ConnectHEOR